These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1094 related articles for article (PubMed ID: 471128)

  • 21. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
    Seigler HF; Shingleton WW; Pickrell KL
    Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
    Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
    [No Abstract]   [Full Text] [Related]  

  • 23. Immune response and non-specific immunotherapy in melanoma.
    El-Domeiri AA
    Ann R Coll Surg Engl; 1978 Mar; 60(2):117-20. PubMed ID: 637492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of intra-lesional injection of tuberculin-active protein on metastatic nodules of human malignant melanoma].
    Saida T
    Nihon Hifuka Gakkai Zasshi; 1982 Nov; 92(13):1399-414. PubMed ID: 6984865
    [No Abstract]   [Full Text] [Related]  

  • 25. Intralesional BCG application in malignant melanoma.
    Sopková B; Kolár V
    Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of malignant skin tumours with oral administration of BCG in enteric-coated capsules.
    Ishihara K; Ikeda S; Arai E; Sawada T
    Dev Biol Stand; 1986; 58 ( Pt A)():465-74. PubMed ID: 3596050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
    Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
    J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
    [No Abstract]   [Full Text] [Related]  

  • 28. Progress of immunotherapy in the treatment of malignant melanoma.
    Ariyan S
    Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
    [No Abstract]   [Full Text] [Related]  

  • 29. [Intralesional application of BCG].
    Kubíková M; Richter J; Hrivnáková J; Duchková H
    Cesk Dermatol; 1980 Aug; 55(4):280-1. PubMed ID: 7407971
    [No Abstract]   [Full Text] [Related]  

  • 30. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cancer immunotherapy in dermatological view (author's transl)].
    Lübbe D; Gstöttner R
    Arch Geschwulstforsch; 1980; 50(2):182-5. PubMed ID: 7436703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunologic aspects of the treatment of melanoma].
    Pawlowska EM
    Pol Tyg Lek; 1977 Jun; 32(24):939-41. PubMed ID: 882435
    [No Abstract]   [Full Text] [Related]  

  • 33. [Immunological aspects of melanoma].
    Sjögren H
    Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
    [No Abstract]   [Full Text] [Related]  

  • 34. [Unspecific, active BCG vaccination therapy in melanoma using a modified scarification procedure].
    Wolf M; Menzel W; Keller G
    Dermatol Monatsschr; 1978 Apr; 164(4):302-3. PubMed ID: 668966
    [No Abstract]   [Full Text] [Related]  

  • 35. [Possibilities of an immunotherapy of malignant skin tumors with particular consideration of malignant melanomas (author's transl)].
    Schöpf E
    Ther Umsch; 1976 Aug; 33(8):538-42. PubMed ID: 1006610
    [No Abstract]   [Full Text] [Related]  

  • 36. Cromolyn prevents bronchospastic attacks caused by Bacillus Calmette Geurin immunotherapy for malignant melanoma patient.
    Wishnitzer R; Eliraz A; Fink A
    Ann Allergy; 1985 Aug; 55(2):167-9. PubMed ID: 3927789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
    Thatcher N; Crowther D
    Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunology and cutaneous malignant melanoma.
    Sober AJ
    Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
    [No Abstract]   [Full Text] [Related]  

  • 39. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
    Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
    Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ["Pathomorphosis" of skin melanomas in the comprehensive treatment using hyperthermia].
    Aleksandrov NN; Neborak IuT; Furmanchuk AV; Zhavrid EA; Fradkin SZ
    Vopr Onkol; 1979; 25(1):19-26. PubMed ID: 425393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.